Syk 'Em? Rigel Says RA Data Not Far from Pfizer's Phase III
Analysts took as less serious one of two primary endpoints that fostamatinib, the oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis (RA), missed in Phase III trial, and focused skeptically instead on the successfully reached goal in the study, known as OSKIRA-1.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter